MALVERN, Pa. — November 20, 2025 — Leads & Copy — Ocugen, Inc. (NASDAQ: OCGN) Chairman, CEO, and Co-founder Dr. Shankar Musunuri will present at NobleCon21, Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference in Boca Raton, FL.
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced that Dr. Musunuri will present at the conference held at Florida Atlantic University, Executive Education Complex.
Dr. Musunuri said he is looking forward to sharing the company’s progress toward its goal of achieving three Biologics License Applications (BLAs) in three years, and providing updates on near-term catalysts in 2026. He also noted that NobleCon provides a forum to differentiate Ocugen’s scientific platform among its peers in ophthalmology and share how the company is addressing major blindness diseases with a single, one-time gene therapy for life.
The presentation and fireside chat will take place on Wednesday, December 3, 2025, at 1 p.m. ET in Presentation Room 2.
In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will conduct one-on-one meetings with investors to highlight the company’s business and clinical development strategy across its modifier gene therapy platform.
A high-definition video webcast of the presentation will be available the following day on Ocugen’s website, as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website and on Channelchek, the investor portal created by Noble. The webcast will be archived on the Company’s website, the NobleCon website, and Channelchek.com for 90 days following the event.
Ocugen is a biotechnology company focused on gene therapies for blindness diseases. The company’s modifier gene therapy platform has the potential to address unmet medical needs for large patient populations through its gene-agnostic approach. Ocugen has programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration.
Noble Capital Markets, Inc. was established in 1984. It is an SEC/FINRA registered full-service broker-dealer offering investment/merchant banking and advisory services. Noble provides middle-market expertise to entrepreneurs, corporations, financial sponsors, and investors. Noble hosts multi-sector virtual conferences throughout the year.
Over its more than 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
Source: Ocugen, Inc.
